Toxicity of iron overload and iron overload reduction in the setting of hematopoietic stem cell transplantation for hematologic malignancies

Alessandrino, 2010, Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study, Haematologica, 95, 476, 10.3324/haematol.2009.011429 Alessandrino, 2011, Iron overload and iron chelation therapy in patients with myelodysplastic syndrome treated by allogeneic stem-cell transplantation: report from the working conference on iron chelation of the Gruppo Italiano Trapianto di Midollo Osseo, Am. J. Hematol., 86, 897, 10.1002/ajh.22104 Altes, 2002, Iron overload might increase transplant-related mortality in haematopoietic stem cell transplantation, Bone Marrow Transplant., 29, 987, 10.1038/sj.bmt.1703570 Altes, 2004, Frequent severe liver iron overload after stem cell transplantation and its possible association with invasive aspergillosis, Bone Marrow Transplant., 34, 505, 10.1038/sj.bmt.1704628 Altes, 2007, Early clinical impact of iron overload in stem cell transplantation. A prospective study, Ann. Hematol., 86, 443, 10.1007/s00277-007-0266-x Angelucci, 1997, Phlebotomy to reduce iron overload in patients cured of thalassemia by bone marrow transplantation. Italian Cooperative Group for Phlebotomy Treatment of Transplanted Thalassemia Patients, Blood, 90, 994, 10.1182/blood.V90.3.994 Angelucci, 2014, Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial), Eur. J. Haematol., 92, 527, 10.1111/ejh.12300 Armand, 2007, Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation, Blood, 109, 4586, 10.1182/blood-2006-10-054924 Armand, 2011, Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantation, Biol. Blood Marrow Transplant., 17, 852, 10.1016/j.bbmt.2010.09.006 Armand, 2012, Does iron overload really matter in stem cell transplantation?, Am. J. Hematol., 87, 569, 10.1002/ajh.23188 Armand, 2013, Pre-transplantation iron chelation in patients with MDS or acute leukemia and iron overload undergoing myeloablative allo-SCT, Bone Marrow Transplant., 48, 146, 10.1038/bmt.2012.94 Armand, 2014, Iron overload in allogeneic hematopoietic cell transplantation outcome: a meta-analysis, Biol. Blood Marrow Transplant., 20, 1248, 10.1016/j.bbmt.2014.04.024 Auberger, 2013, Non-invasive transient elastography for the prediction of liver toxicity following hematopoietic SCT, Bone Marrow Transplant., 48, 159, 10.1038/bmt.2012.113 Balducci, 2006, Transfusion independence in patients with myelodysplastic syndromes: impact on outcomes and quality of life, Cancer, 106, 2087, 10.1002/cncr.21860 Bazuaye, 2012, Prognostic impact of iron parameters in patients undergoing allo-SCT, Bone Marrow Transplant., 47, 60, 10.1038/bmt.2011.13 Bennett, 2008, Consensus statement on iron overload in myelodysplastic syndromes, Am. J. Hematol., 83, 858, 10.1002/ajh.21269 Busca, 2010, Iron overload in patients receiving allogeneic hematopoietic stem cell transplantation: quantification of iron burden by a superconducting quantum interference device (SQUID) and therapeutic effectiveness of phlebotomy, Biol. Blood Marrow Transplant., 16, 115, 10.1016/j.bbmt.2009.09.011 Cantinieaux, 1990, Desferrioxamine improves neutrophil phagocytosis in thalassemia major, Am. J. Hematol., 35, 13, 10.1002/ajh.2830350104 Cantinieaux, 1999, Ferritin-associated iron induces neutrophil dysfunction in hemosiderosis, J. Lab. Clin. Med., 133, 353, 10.1016/S0022-2143(99)90066-5 Carmine, 1995, Presence of iron catalytic for free radical reactions in patients undergoing chemotherapy: implications for therapeutic management, Cancer Lett., 94, 219, 10.1016/0304-3835(95)03852-N Carmona, 2014, Ferritin light-chain subunits: key elements for the electron transfer across the protein cage, Chem. Commun. (Camb.), 50, 15358, 10.1039/C4CC07996E Cetin, 2004, Oxidative stress in patients undergoing high-dose chemotherapy plus peripheral blood stem cell transplantation, Biol. Trace Elem. Res., 97, 237, 10.1385/BTER:97:3:237 Chacko, 2007, Myocardial iron loading by magnetic resonance imaging T2* in good prognostic myelodysplastic syndrome patients on long-term blood transfusions, Br. J. Haematol., 138, 587, 10.1111/j.1365-2141.2007.06695.x Chan, 2010, Iron overload accelerates development of leukaemia: evidence from a mouse model, Blood, 116, 10.1182/blood.V116.21.122.122 Cheung, 2008, Effect of deferasirox (ICL670) on arterial function in patients with beta-thalassaemia major, Br. J. Haematol., 141, 728, 10.1111/j.1365-2141.2008.07092.x Cilloni, 2011, High rate of erythroid response during iron chelation therapy in a cohort of 105 patients affected by hematologic malignancies with transfusional iron overload: an italian multicenter retrospective study, Blood, 10.1182/blood.V118.21.611.611 Cutler, 2004, A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome, Blood, 104, 579, 10.1182/blood-2004-01-0338 Dadwal, 2015, Impact of pretransplant serum ferritin level on risk of invasive mold infection after allogeneic hematopoietic stem cell transplantation, Eur. J. Haematol., 94, 235, 10.1111/ejh.12421 Davis, 2000, Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia, Blood, 95, 1229, 10.1182/blood.V95.4.1229.004k32_1229_1236 Davis, 2004, Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major, Blood, 104, 263, 10.1182/blood-2003-08-2841 de Swart, 2010, Disease-managment of low- and intermediate-1 risk myelodysplastic syndromes: report on 800 newly diagnosed MDS patients from the European LeukemiaNet MDS Registry, Blood, 116, 1201 De Swart, 2011, Transfusion-dependency is the most important prognostic factor for survival in 1000 newly diagnosed MDS pateints with low- and intermediate-1 risk MDS in the European LeukemiaNet MDS Registry, Blood, 118, 1195, 10.1182/blood.V118.21.2775.2775 De Swart, 2015, Labile Plasma Iron (LPI) is a clinical indicator of overt iron overload in patients with lower-risk Myelodysplastic Syndromes (MDS) from the European Leukemianet MDS Registry, Blood, 126, 10.1182/blood.V126.23.2865.2865 Delforge, 2014, Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes, Leuk. Res., 38, 557, 10.1016/j.leukres.2014.02.003 Di Tucci, 2008, Myocardial iron overload assessment by T2* magnetic resonance imaging in adult transfusion dependent patients with acquired anemias, Haematologica, 93, 1385, 10.3324/haematol.12759 Durken, 1997, Nontransferrin-bound iron in serum of patients receiving bone marrow transplants, Free Radic. Biol. Med., 22, 1159, 10.1016/S0891-5849(96)00497-2 Evans, 2008, Nature of non-transferrin-bound iron: studies on iron citrate complexes and thalassemic sera, J. Biol. Inorg. Chem., 13, 57 Evens, 2004, Rust and corrosion in hematopoietic stem cell transplantation: the problem of iron and oxidative stress, Bone Marrow Transplant., 34, 561, 10.1038/sj.bmt.1704591 Ezzat, 2012, Association between increased liver iron concentration and vitamin D deficiency in patients with transfusion dependent hemoglobinopathies in British Columbia, Blood, 120, 10.1182/blood.V120.21.3203.3203 Fenaux, 2009, Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study, Lancet Oncol., 10, 223, 10.1016/S1470-2045(09)70003-8 Gabutti, 1996, Results of long-term iron-chelating therapy, Acta Haematol., 95, 26, 10.1159/000203853 Ganz, 2012, Hepcidin and iron homeostasis, Biochim. Biophys. Acta, 1823, 1434, 10.1016/j.bbamcr.2012.01.014 Garcia-Vidal, 2008, Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation, Clin. Infect. Dis., 47, 1041, 10.1086/591969 Gattermann, 2008, Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload, Int. J. Hematol., 88, 24, 10.1007/s12185-008-0118-z Gattermann, 2011, Iron overload in MDS-pathophysiology, diagnosis, and complications, Ann. Hematol., 90, 1, 10.1007/s00277-010-1091-1 Gattermann, 2010, Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: results from the large 1-year EPIC study, Leuk. Res., 34, 1143, 10.1016/j.leukres.2010.03.009 Gattermann, 2012, Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes, Haematologica, 97, 1364, 10.3324/haematol.2011.048546 Gattermann, 2013, Estimation of the relationship between serum ferritin and liver iron concentration in patients with myelodysplastic syndromes, European Hematology Association Meeting Gaziev, 2005, Bone marrow transplantation in adults with thalassemia: treatment and long-term follow-up, Ann. N. Y. Acad. Sci., 1054, 196, 10.1196/annals.1345.024 Ghoti, 2010, Changes in parameters of oxidative stress and free iron biomarkers during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndromes, Haematologica, 95, 1433, 10.3324/haematol.2010.024992 Glickstein, 2006, Action of chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequences, Blood, 108, 3195, 10.1182/blood-2006-05-020867 Greenberg, 1997, International scoring system for evaluating prognosis in myelodysplastic syndromes, Blood, 89, 2079, 10.1182/blood.V89.6.2079 Greenberg, 2011, NCCN clinical practice guidelines in oncology: myelodysplastic syndromes, JNCCN, 9, 30 Greenberg, 2012, Revised international prognostic scoring system for myelodysplastic syndromes, Blood, 120, 2454, 10.1182/blood-2012-03-420489 Grossekatthofer, 2013, Ferritin concentrations correlate to outcome of hematopoietic stem cell transplantation but do not serve as biomarker of graft-versus-host disease, Ann. Hematol., 92, 1121, 10.1007/s00277-013-1737-x Guyatt, 2006, Grading strength of recommendations and quality of evidence in clinical guidelines: report from an american college of chest physicians task force, Chest, 129, 174, 10.1378/chest.129.1.174 Harrison, 1996, Role of non-transferrin bound iron in iron overload and liver dysfunction in long term survivors of acute leukaemia and bone marrow transplantation, J. Clin. Pathol., 49, 853, 10.1136/jcp.49.10.853 Hellstrom-Lindberg, 2005, Management of anemia associated with myelodysplastic syndrome, Semin. Hematol., 42, S10, 10.1053/j.seminhematol.2005.01.002 Hentze, 2004, Balancing acts: molecular control of mammalian iron metabolism, Cell, 117, 285, 10.1016/S0092-8674(04)00343-5 Jaekel, 2016, Efficacy and safety of deferasirox in non-thalassemic patients with elevated ferritin levels after allogeneic hematopoietic stem cell transplantation, Bone Marrow Transplant., 51, 89, 10.1038/bmt.2015.204 Jensen, 2003, Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool, Blood, 101, 4632, 10.1182/blood-2002-09-2754 Kaloyannidis, 2010, The impact of desferrioxamine postallogeneic hematopoietic cell transplantation in relapse incidence and disease-free survival: a retrospective analysis, Transplantation, 89, 472, 10.1097/TP.0b013e3181c42944 Kamble, 2006, Iron overload manifesting as apparent exacerbation of hepatic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation, Biol. Blood Marrow Transplant., 12, 506, 10.1016/j.bbmt.2006.01.004 Kanda, 2008, Serum hepcidin level and erythropoietic activity after hematopoietic stem cell transplantation, Haematologica, 93, 1550, 10.3324/haematol.12399 Kantarjian, 2008, Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System, Cancer, 113, 1351, 10.1002/cncr.23697 Karlas, 2014, Value of liver elastography and abdominal ultrasound for detection of complications of allogeneic hemopoietic SCT, Bone Marrow Transplant., 49, 806, 10.1038/bmt.2014.61 Kataoka, 2009, Influence of pretransplantation serum ferritin on nonrelapse mortality after myeloablative and nonmyeloablative allogeneic hematopoietic stem cell transplantation, Biol. Blood Marrow Transplant., 15, 195, 10.1016/j.bbmt.2008.11.012 Kautz, 2014, Identification of erythroferrone as an erythroid regulator of iron metabolism, Nat. Genet., 46, 678, 10.1038/ng.2996 Kew, 2015, A prospective cohort study of the feasibility and efficacy of iron reduction by phlebotomy in recipients of hematopoietic SCT, Bone Marrow Transplant., 50, 457, 10.1038/bmt.2014.273 Komrokji, 2011, Impact of iron chelation therapy on overall survival and AML transformation in lower risk MDS patients treated at the moffitt cancer center, Blood, 118, 10.1182/blood.V118.21.2776.2776 Konen, 2007, No evidence for myocardial iron overload in multitransfused patients with myelodysplastic syndrome using cardiac magnetic resonance T2 technique, Am. J. Hematol., 82, 1013, 10.1002/ajh.20980 Koreth, 2013, Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis, J. Clin. Oncol., 31, 2662, 10.1200/JCO.2012.46.8652 Lee, 2009, Effect of iron overload and iron-chelating therapy on allogeneic hematopoietic SCT in children, Bone Marrow Transplant., 44, 793, 10.1038/bmt.2009.88 Leitch, 2011, Controversies surrounding iron chelation therapy for MDS, Blood Rev., 25, 17, 10.1016/j.blre.2010.09.003 Leitch, 2008, Improved survival in patients with myelodysplastic syndrome receiving iron chelation therapy, Clin. Leuk., 2, 205, 10.3816/CLK.2008.n.026 Lim, 2010, Impact of pre-transplant serum ferritin on outcomes of patients with myelodysplastic syndromes or secondary acute myeloid leukaemia receiving reduced intensity conditioning allogeneic haematopoietic stem cell transplantation, Leuk. Res., 34, 723, 10.1016/j.leukres.2009.10.028 List, 2012, Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome, J. Clin. Oncol., 30, 2134, 10.1200/JCO.2010.34.1222 Lucarelli, 1990, Bone marrow transplantation in patients with thalassemia, N. Engl. J. Med., 322, 417, 10.1056/NEJM199002153220701 Lucarelli, 1993, Fate of iron stores in thalassaemia after bone-marrow transplantation, Lancet, 342, 1388, 10.1016/0140-6736(93)92753-G Lyons, 2014, Comparison of 24-month outcomes in chelated and non-chelated lower-risk patients with myelodysplastic syndromes in a prospective registry, Leuk. Res., 38, 149, 10.1016/j.leukres.2013.11.004 Mahindra, 2008, Elevated ferritin is associated with relapse after autologous hematopoietic stem cell transplantation for lymphoma, Biol. Blood Marrow Transplant., 14, 1239, 10.1016/j.bbmt.2008.08.009 Mahindra, 2009, Elevated pretransplant serum ferritin is associated with inferior survival following nonmyeloablative allogeneic transplantation, Bone Marrow Transplant. Majhail, 2010, A prospective study of iron overload management in allogeneic hematopoietic cell transplantation survivors, Biol. Blood Marrow Transplant., 16, 832, 10.1016/j.bbmt.2010.01.004 Malcovati, 2005, Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making, J. Clin. Oncol., 23, 7594, 10.1200/JCO.2005.01.7038 Malcovati, 2006, Predicting survival and leukemic evolution in patients with myelodysplastic syndrome, Haematologica, 91, 1588 Malcovati, 2007, Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes, J. Clin. Oncol., 25, 3503, 10.1200/JCO.2006.08.5696 Maradei, 2009, Serum ferritin as risk factor for sinusoidal obstruction syndrome of the liver in patients undergoing hematopoietic stem cell transplantation, Blood, 114, 1270, 10.1182/blood-2009-03-212282 Marek, 2013, 48-month update on survival and AML transformation in a 600-patient registry of lower-risk MDS patients, Blood, 122 McKay, 1996, Iron overload and liver dysfunction after allogeneic or autologous bone marrow transplantation, Bone Marrow Transplant., 17, 63 Meyer, 2013, Prognostic impact of posttransplantation iron overload after allogeneic stem cell transplantation, Biol. Blood Marrow Transplant., 19, 440, 10.1016/j.bbmt.2012.10.012 Miceli, 2006, Iron overload is a major risk factor for severe infection after autologous stem cell transplantation: a study of 367 myeloma patients, Bone Marrow Transplant., 37, 857, 10.1038/sj.bmt.1705340 Michallet, 2013, Significant impact of iron chelation after allogeneic hematopoietic stem cell transplantation on disease recurrence: potential anti-leukemic activity, Blood, 122, 10.1182/blood.V122.21.180.180 Morgenthau, 2013, Bacterial receptors for host transferrin and lactoferrin: molecular mechanisms and role in host-microbe interactions, Future Microbiol., 8, 1575, 10.2217/fmb.13.125 Naoum, 2014, Assessment of labile plasma iron in patients who undergo hematopoietic stem cell transplantation, Acta Haematol., 131, 222, 10.1159/000355192 2016 2016 2016 Neukirchen, 2012, Improved survival in MDS patients receiving iron chelation therapy – a matched pair analysis of 188 patients from the Dusseldorf MDS registry, Leuk. Res., 36, 1067, 10.1016/j.leukres.2012.04.006 Nolte, 2013, Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload, Ann. Hematol., 92, 191, 10.1007/s00277-012-1594-z Olivieri, 1997, Iron-chelating therapy and the treatment of thalassemia, Blood, 89, 739, 10.1182/blood.V89.3.739 Ozyilmaz, 2010, Risk factors for fungal pulmonary infections in hematopoietic stem cell transplantation recipients: the role of iron overload, Bone Marrow Transplant. Pascal, 2013, Cardiac iron overload assessed by T2* magnetic resonance imaging and cardiac function in regularly transfused myelodysplastic syndrome patients, Br. J. Haematol., 162, 413, 10.1111/bjh.12368 Platzbecker, 2008, Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS), Biol. Blood Marrow Transplant., 14, 1217, 10.1016/j.bbmt.2008.08.006 Porter, 2005, Recent insights into interactions of deferoxamine with cellular and plasma iron pools: implications for clinical use, Ann. N. Y. Acad. Sci., 1054, 155, 10.1196/annals.1345.018 Porter, 2014, Insights into relationships between serum ferritin and liver iron concentration trends during 12 months of iron chelation therapy with deferasirox – a post-hoc analysis from the epic study, Blood, 124, 10.1182/blood.V124.21.52.52 Pullarkat, 2009, Objectives of iron chelation therapy in myelodysplastic syndromes: more than meets the eye?, Blood, 114, 5251, 10.1182/blood-2009-07-234062 Pullarkat, 2008, Iron overload adversely affects outcome of allogeneic hematopoietic cell transplantation, Bone Marrow Transplant., 42, 799, 10.1038/bmt.2008.262 Rassool, 2007, Reactive oxygen species, DNA damage, and error-prone repair: a model for genomic instability with progression in myeloid leukemia?, Cancer Res., 67, 8762, 10.1158/0008-5472.CAN-06-4807 Remacha, 2015, Evolution of iron overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ complications, Ann. Hematol., 94, 779, 10.1007/s00277-014-2274-y Rose, 2007, Quantification by magnetic resonance imaging and liver consequences of post-transfusional iron overload alone in long term survivors after allogeneic hematopoietic stem cell transplantation (HSCT), Haematologica, 92, 850, 10.3324/haematol.11063 Rose, 2010, Does iron chelation therapy improve suvival in regularly transfused lower risk MDS patients? A multicenter study by the GFM, Leuk. Res., 34, 864, 10.1016/j.leukres.2009.12.004 Roy, 2011, Cardiac iron overload in transfusion-dependent patients with myelodysplastic syndromes, Br. J. Haematol., 154, 521, 10.1111/j.1365-2141.2011.08749.x Sahlstedt, 2001, Non-transferrin-bound iron during allogeneic stem cell transplantation, Br. J. Haematol., 113, 836, 10.1046/j.1365-2141.2001.02820.x Sahlstedt, 2009, Non-transferrin-bound iron in haematological patients during chemotherapy and conditioning for autologous stem cell transplantation, Eur. J. Haematol., 83, 455, 10.1111/j.1600-0609.2009.01310.x Sallmyr, 2008, Genomic instability in myeloid malignancies: increased reactive oxygen species (ROS), DNA double strand breaks (DSBs) and error-prone repair, Cancer Lett., 270, 1, 10.1016/j.canlet.2008.03.036 Santini, 2010, Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines, Leuk. Res., 34, 1576, 10.1016/j.leukres.2010.01.018 Santini, 2011, Hepcidin levels and their determinants in different types of myelodysplastic syndromes, PLoS ONE, 6, e23109, 10.1371/journal.pone.0023109 Sanz, 2008, Independent impact of iron overload and transfusion dependency on survival and leukemic evolution in patients with myelodysplastic syndrome, Blood, 112, 238, 10.1182/blood.V112.11.640.640 Schanz, 2012, New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge, J. Clin. Oncol., 30, 820, 10.1200/JCO.2011.35.6394 Sivgin, 2012, Pretransplant serum ferritin level may be a predictive marker for outcomes in patients having undergone allogeneic hematopoietic stem cell transplantation, Neoplasma, 59, 183, 10.4149/neo_2012_024 Sivgin, 2013, The oral iron chelator deferasirox might improve survival in allogeneic hematopoietic cell transplant (alloHSCT) recipients with transfusional iron overload, Transfus. Apher. Sci., 49, 295, 10.1016/j.transci.2013.07.004 Sorror, 2009, Low albumin, high ferritin, and thrombocytopenia before transplant predict non-relapse mortality (NRM) independent of the hematopoietic cell transplantation comorbidity index (HCT-CI), Blood, 114, 271a, 10.1182/blood.V114.22.651.651 Statistics Canada, 2012 Storey, 2009, The transplant iron score as a predictor of stem cell transplant survival, J. Hematol. Oncol., 2, 44, 10.1186/1756-8722-2-44 Tachibana, 2011, Pretransplant serum ferritin is associated with bloodstream infections within 100 days of allogeneic stem cell transplantation for myeloid malignancies, Int. J. Hematol., 93, 368, 10.1007/s12185-011-0784-0 Tachibana, 2012, Pretransplant serum ferritin has a prognostic influence on allogeneic transplant regardless of disease risk, Leuk. Lymphoma, 53, 456, 10.3109/10428194.2011.619607 Taher, 2011, Optimal management of beta thalassaemia intermedia, Br. J. Haematol., 152, 512, 10.1111/j.1365-2141.2010.08486.x Takatoku, 2007, Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality, Eur. J. Haematol., 78, 487, 10.1111/j.1600-0609.2007.00842.x Tanaka, 2015, Clinical significance of pretransplant serum ferritin on the outcome of allogeneic hematopoietic SCT: a prospective cohort study by the Kanto Study Group for Cell Therapy, Bone Marrow Transplant., 50, 727, 10.1038/bmt.2015.17 Themeli, 2010, Alloreactive microenvironment after human hematopoietic cell transplantation induces genomic alterations in epithelium through an ROS-mediated mechanism: in vivo and in vitro study and implications to secondary neoplasia, Leukemia, 24, 536, 10.1038/leu.2009.284 Tomas, 2000, Long-term liver dysfunction after allogeneic bone marrow transplantation: clinical features and course in 61 patients, Bone Marrow Transplant., 26, 649, 10.1038/sj.bmt.1702532 Tortorella, 2014, The significance of transferrin receptors in oncology: the development of functional nano-based drug delivery systems, Curr. Drug Deliv., 11, 427, 10.2174/1567201810666140106115436 Trottier, 2013, Association of iron overload with allogeneic hematopoietic cell transplantation outcomes: a prospective cohort study using R2-MRI-measured liver iron content, Blood, 122, 1678, 10.1182/blood-2013-04-499772 Vallejo, 2014, Phase IV open-label study of the efficacy and safety of deferasirox after allogeneic stem cell transplantation, Haematologica, 99, 1632, 10.3324/haematol.2014.105908 van Asbeck, 1984, Functional defects in phagocytic cells from patients with iron overload, J. Infect., 8, 232, 10.1016/S0163-4453(84)93955-0 van Asbeck, 1984, Deferoxamine enhances phagocytic function of human polymorphonuclear leukocytes, Blood, 63, 714, 10.1182/blood.V63.3.714.714 Vardiman, 2002, The World Health Organization (WHO) classification of the myeloid neoplasms, Blood, 100, 2292, 10.1182/blood-2002-04-1199 Vaughn, 2015, Design and validation of an augmented hematopoietic cell transplantation-comorbidity index comprising pretransplant ferritin, albumin, and platelet count for prediction of outcomes after allogeneic transplantation, Biol. Blood Marrow Transplant., 21, 1418, 10.1016/j.bbmt.2015.04.002 Virtanen, 2013, Prognostic impact of pretransplant iron overload measured with magnetic resonance imaging on severe infections in allogeneic stem cell transplantation, Eur. J. Haematol., 91, 85, 10.1111/ejh.12123 Visani, 2014, Deferasirox improves hematopoiesis after allogeneic hematopoietic SCT, Bone Marrow Transplant., 49, 585, 10.1038/bmt.2013.213 Wahlin, 2011, Hyperferritinemia is associated with low incidence of graft versus host disease, high relapse rate, and impaired survival in patients with blood disorders receiving allogeneic hematopoietic stem cell grafts, Med. Oncol., 28, 552, 10.1007/s12032-010-9496-1 Wells, 2008, Iron overload in myelodysplastic syndromes: a Canadian consensus guideline, Leuk. Res., 32, 1338, 10.1016/j.leukres.2008.02.021 Wermke, 2012, MRI-based liver iron content predicts for nonrelapse mortality in MDS and AML patients undergoing allogeneic stem cell transplantation, Clin. Cancer Res., 18, 6460, 10.1158/1078-0432.CCR-12-1683 Wermke, 2015, The Extent of Labile Plasma Iron (LPI) Predicts for Non-Relapse-Mortality (NRM) in AML and MDS patients with systemic iron overload undergoing allogenic stem cell transplantation results of the prospective, German-Austrian allive trial, Blood, 126, 10.1182/blood.V126.23.386.386 Williamson, 1994, Establishing the incidence of myelodysplastic syndrome, Br. J. Haematol., 87, 743, 10.1111/j.1365-2141.1994.tb06733.x Winder, 2008, Urinary hepcidin excretion in patients with myelodysplastic syndrome and myelofibrosis, Br. J. Haematol., 142, 669, 10.1111/j.1365-2141.2008.07225.x Zeidan, 2015, Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromes, J. Comp. Eff. Res., 4, 327, 10.2217/cer.15.20